NEW YORK (GenomeWeb) – Pacific Biosciences and Oxford Nanopore Technologies have entered into a five-year settlement of a patent infringement dispute in Europe.
Under the terms of the agreement, Oxford Nanopore will not sell its 2D sequencing products in the UK or in Germany through the end of 2023. In addition, Oxford Nanopore has agreed to dismiss a countersuit it had brought against PacBio in those countries.
To read the full story….
…and receive Daily News bulletins.
Already have an account?